Lymphedema Treatment Act
Society Continues Supports for Lymphedema Treatment Act
WOCN renewed our grassroots/advocacy efforts for the 117th Congress in support of the Lymphedema Treatment Act. As you may recall, the legislation would amend Medicare statute to pay for compression garments, bandages and supplies to reduce lymphedema-related swelling and prevent recurrence. Compression therapy is considered the gold standard for the treatment of lymphedema and the treatment and prevention of venous leg ulcers (VLUs), also known as stasis ulcers. The WOCN Society strongly supports the Lymphedema Treatment Act; this legislation reflects the vision and core tenets of the WOCN Society as a means to support cost-effective, evidence-based prevention and treatment of complex wound conditions such as VLUs and lymphedema.
WOCN also provided support for an independent cost analysis/impact study regarding the Lymphedema Treatment Act. Avalere recently completed a savings analysis showing that enactment of the Lymphedema Treatment Act (S.1315/H.R.3630) will save the Medicare program a substantial amount – $1.3 to $1.5 billion during the first 10 years, with additional savings likely. Savings will also result in the Medicaid and private insurance categories. Given this new savings information, plus the broad bipartisan and bicameral support for the bill, which currently has 71 Senate and 324 House cosponsors, we hope to see it included in a legislative package during the second term of this Congress. WOCN plans to send letters to House and Senate leadership in the coming weeks urging them to pass the legislation.